Sonnet BioTherapeutics Holdings (SONN) said Wednesday it has received a patent from the US Patent and Trademark Office for its SON-1411 and SON-1400 immunotherapeutic drug candidates.
The patent, which covers a variant of recombinant human interleukin-18 contained in the two drug candidates, is effective until June 2044, Sonnet said.
SON-1411, a bifunctional fusion protein, and SON-1400, a monofunctional fusion protein, are linked to Sonnet's fully human albumin binding platform, the company said.
Shares of Sonnet rose more than 119% in early Wednesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments